Outlook Therapeutics, Inc.
OTLK
$1.45
$0.085.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 255.46% | 143.81% | 314.80% | -1,617.52% | 40.10% |
| Total Depreciation and Amortization | 2.13% | 157.14% | 156.25% | 156.36% | 161.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,622.33% | -1,308.94% | -1,542.25% | 6,850.79% | -29.58% |
| Change in Net Operating Assets | 264.09% | 312.25% | -156.72% | 55.84% | -164.98% |
| Cash from Operations | 15.84% | -33.28% | -47.64% | -137.44% | -46.41% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | 62.07% | 99.97% |
| Issuance of Common Stock | -- | -- | 30.56% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54,550.00% | -104.74% | 30.68% | 9,502.09% | -100.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 29.23% | -65.71% | -53.27% | 523.25% | -137.30% |